Gene And Cell Therapy Products Community

 View Only

  • 1.  OSD: QUANTITATIVE MODELING APPROACHES FOR LNP-MRNA THERAPEUTICS

    Community Leadership
    Posted 07-30-2024 10:55

    Please join us for an Open Scientific Discussion (OSD) hosted by the AAPS Gene and Cell Therapy Products (GCTPs) Community on Aug 8, 2024, 12 pm- 1 pm EDT on the following topic:

    "Quantitative modeling approaches for LNP-mRNA therapeutics"

    • Why are quantitative approaches important for LNP-mRNA product development during preclinical and clinical stages?

    • What are the key features and challenges when applying quantitative approaches for LNP-mRNA therapeutics?

    • How to build and implement quantitative approaches for LNP-mRNA therapeutics?

    Discussion Leaders:

    Saroja Ramanujan, previous Executive Director, Translational Sciences & Pharmacology, Head of QSP, Genentech

    Hojjat Bazzazi, Director, Quantitative System Pharmacology, Moderna

    Min Liang, Associate Director, Pharmacometrics, Moderna

    Organized by: 

    Dale Miles (Genentech), Yun Liu (Moderna), Yan Ni (Passage Bio), Yanmei Lu (Sangamo Therapeutics)

    We start at 12:00 EDT sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.

    (Please remain on mute unless asking questions)

    Please feel free to share with colleagues who may be interested in this topic.

    Login Details Below:

    When: Thursday, Aug 8, 2024:  12 pm to 1 pm EDT

    Where: Please join from your computer, tablet or smartphone.
    https://meet.goto.com/505947717

    You can also dial in using your phone.
    United States: +1 (646) 749-3122

    Access Code:  505-947-717

    Join from a video-conferencing room or system.
    Dial in or type:  67.217.95.2 or inroomlink.goto.com

    Meeting ID: 505-947-717

    Or dial directly:  [email protected] or 67.217.95.2##505947717

    New to GoToMeeting? Get the app now and be ready when your first meeting starts:
    https://meet.goto.com/install

     

    Please feel free to share with colleagues who may be interested in this topic.

    The Leadership Team of the AAPS GCTP Community



    ------------------------------
    Dale Miles
    Distinguished Scientist, Clinical Pharmacology
    Genentech
    South San Francisco CA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: OSD: QUANTITATIVE MODELING APPROACHES FOR LNP-MRNA THERAPEUTICS

    Community Leadership
    Posted 07-31-2024 09:16

    Thanks Dale for organizing and sharing this OSD.

    LNP-mRNA PK/PD has been limited, so this will be a great introduction to the challenges and opportunities of this newer therapeutic modality.  I am looking foward to hearing more from this OSD.

    Cheers,

    Steven-



    ------------------------------
    Steven Louie M.S.
    Associate Director
    Moderna
    Cambridge MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------

    Original Message